Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
03/2000
03/30/2000WO2000016794A1 Neuroimmunophilins for selective neuronal radioprotection
03/30/2000WO2000016767A1 Hydroxamate-containing cysteine and serine protease inhibitors
03/30/2000WO2000016765A1 Method and composition for treatment of inflammatory bowel disease
03/30/2000WO2000016758A2 Treatment of infection
03/30/2000WO2000016750A1 Pharmaceutical composition for the treatment of acute disorders
03/30/2000WO2000016745A2 Micronised pharmaceutical compositions
03/30/2000WO2000016741A1 Method and system for enhancing delivery of an agent
03/30/2000WO2000016631A1 Murf2
03/30/2000WO2000009711A8 ISOLATED AND PURIFIED HUMAN SOLUBLE GUANYLYLCYCLASE α1/β1 (hsGCα1/β1)
03/30/2000WO2000008196A3 Urate oxidase
03/30/2000WO2000002913B1 Chemotaxis-inhibiting protein of staphylococcus (chips) and its use
03/30/2000WO2000002584A3 Cancer treatment methods using antibodies to aminophospholipids
03/30/2000WO2000002576A3 Egf-genistein for prevention of restenosis
03/30/2000WO2000000609A3 Molecules associated with apoptosis
03/30/2000WO2000000214A3 Pharmaceutical preparations for use in combatting or preventing surface infections caused by microorganisms
03/30/2000WO1999067426A8 Absorptive hypercalciuria locus on human chromosome 1
03/30/2000WO1999067393A3 Aav scleroprotein, production and use thereof
03/30/2000WO1999067288A9 Tumor antigen peptides originating in cyclophilin b
03/30/2000WO1999066959A9 Compositions and methods for delivery of genetic material for altering neuronal growth, regeneration, and survival
03/30/2000WO1999064593A3 Cell cycle regulation proteins
03/30/2000WO1999063931A9 Peptidyl-prolyl cis-trans isomerase inhibitors and uses therefor
03/30/2000WO1999063101A9 Transfected cells and methods for treating diabetes
03/30/2000WO1999062536A3 Pharmaceutical formulations for igf/igfbp
03/30/2000WO1999061608A3 Polypeptides from creb binding protein and related protein p300 for use in transcriptional regulation
03/30/2000WO1999061066A9 Convection-enhanced delivery of aav vectors
03/30/2000WO1999060127A9 Il-17 homologous polypeptides and therapeutic uses thereof
03/30/2000WO1999057565A3 Methods for diagnosing and evaluating cancer
03/30/2000WO1999057281A3 Peptide antibiotics which inhibit the growth of pneumococci, abc transporter and two-component signal transduction system proteins from streptococcus pneumoniae, and methods using the same
03/30/2000WO1999055831A3 Adenoviral vectors for treating disease
03/30/2000WO1999054470A3 Bacterial ygjd polypeptide family
03/30/2000WO1999053091A3 Dna coding for gdnf, parts of said dna and gdnf variants
03/30/2000WO1999053055A3 Therapeutic agent for ngf
03/30/2000WO1999051744A3 A interleukin-1 receptor antagonist and uses thereof
03/30/2000WO1999049892A3 Use of active p40 conjugates for nasal delivery
03/30/2000WO1999042477A3 Transporter protein for saccharide-coupled medicaments
03/30/2000WO1999040932A9 Mixed micellar pharmaceutical delivery system and method of preparation
03/30/2000WO1998053846A9 Use of recombinant human uteroglobin in treatment of inflammatory and fibrotic conditions
03/30/2000DE19842363A1 Use of chemokines, especially HCC-2 for mobilising haematopoietic stem cells, progenitor cells and mature leukocytes from the bone marrow into the blood stream
03/30/2000CA2820588A1 Pharmaceutical composition for the treatment of acute disorders
03/30/2000CA2689373A1 G protein-coupled receptor antagonists
03/30/2000CA2345397A1 Trophoblast cell preparations
03/30/2000CA2345378A1 Neuroimmunophilins for selective neuronal radioprotection
03/30/2000CA2345088A1 Gpr10 as a target for identifying weight modulating compounds
03/30/2000CA2344657A1 Human isre-binding protein
03/30/2000CA2344440A1 Antibody directed enzyme prodrug therapy (edept) with glucoronidase
03/30/2000CA2344438A1 Method and composition for treatment of inflammatory bowel disease
03/30/2000CA2344370A1 Chemokine receptor antagonist and cyclosporin in combined therapy
03/30/2000CA2344277A1 Cystine knot growth factor mutants
03/30/2000CA2344100A1 31 human secreted proteins
03/30/2000CA2344056A1 Use of glp-1 or analogs in treatment of stroke
03/30/2000CA2343931A1 Human complement c3-degrading polypeptide from streptococcus pneumoniae
03/30/2000CA2343919A1 Genes of the 1-desoxy-d-xylulose biosynthetic pathway
03/30/2000CA2343916A1 Methods of downmodulating the immune response to therapeutic proteins
03/30/2000CA2343718A1 Human chaperone proteins
03/30/2000CA2343360A1 Human cytoskeleton associated proteins
03/30/2000CA2343353A1 Methods and compositions relating to egf-repeat-containing polypeptides
03/30/2000CA2343321A1 Pharmaceutical composition for the pre-treatment of a patient in need of drug or pro-drug
03/30/2000CA2343320A1 Lynx, a novel family of receptor ligands in the central nervous system, corresponding nucleic acids and proteins and uses therof
03/30/2000CA2343193A1 Improved stereoselective process for enalapril
03/30/2000CA2343067A1 Hairpin hybridizer molecules for modulation of gene expression
03/30/2000CA2343052A1 Methods of treating ige-associated disorders and compositions for use therein
03/30/2000CA2343004A1 Alzheimer's disease secretase
03/30/2000CA2342834A1 Preventive and/or therapeutic for obesity
03/30/2000CA2342773A1 Interferon-epsilon
03/30/2000CA2339866A1 Recombinant celo virus and celo virus dna
03/30/2000CA2311407A1 Process for the preparation of n2-(1(s)-carboxy-3-phenylpropyl)-l-lysyl-l-proline
03/29/2000EP0989136A1 Peptides having cyclic structures and exerting p53 protein activty-restoring effect on p53 protein mutants
03/29/2000EP0988861A1 Stabilized protein compositions
03/29/2000EP0988859A1 Active substance preparations and a process for producing the same
03/29/2000EP0988548A1 Inhibition of the src kinase family pathway as a method of treating hbv infection and hepatocellular carcinoma
03/29/2000EP0988388A2 Ghrh expression system and methods of use
03/29/2000EP0988385A2 Tace-like and matrilysin-like polypeptides
03/29/2000EP0988382A1 Human protein phosphatase ii-c-like protein
03/29/2000EP0988381A1 T-cell receptor beta-like protein
03/29/2000EP0988380A1 Translational regulator initiation factor 4e-binding protein
03/29/2000EP0988379A1 Ldl-receptor
03/29/2000EP0988377A1 Zinc finger protein derivatives and methods therefor
03/29/2000EP0988376A2 Noey2 gene compositions and methods of use
03/29/2000EP0988374A1 Hydrophilic composition containing protease produced by vibrio
03/29/2000EP0988371A1 Human tumor necrosis factor receptor tr9
03/29/2000EP0988321A2 B7-binding molecules for treating immune diseases
03/29/2000EP0988320A1 Cyclic crf agonists
03/29/2000EP0988319A1 Human l105 proteins and polynucleotides encoding same
03/29/2000EP0988318A2 Human extracellular matrix proteins
03/29/2000EP0988317A2 Aib1, a steroid receptor co-activator
03/29/2000EP0988316A1 Methods and compositions for diagnosis and treatment of iron overload diseases and iron deficiency diseases
03/29/2000EP0988314A1 Novel synthetic peptides with antimicrobial and endotoxin neutralizing properties for management of the sepsis syndrome
03/29/2000EP0988280A1 Hydroxamic acid compounds having anticancer and anti-parasitic properties
03/29/2000EP0988056A2 Tissue factor methods and compositions for coagulation and tumor treatment
03/29/2000EP0988054A1 Method and compositions for preventing and treating the systemic inflammatory response syndrome including sepsis
03/29/2000EP0988050A1 UTILIZATION OF $i(WOLINELLA SUCCINOGENES) ASPARAGINASE TO TREAT DISEASES ASSOCIATED WITH ASPARAGINE DEPENDENCE
03/29/2000EP0988049A2 Pharmaceutical composition for treating hepatitis b virus (hbv) infection
03/29/2000EP0988048A1 Ligand/lytic peptide compositions and methods of use
03/29/2000EP0988047A1 Soluble ctla4 mutant molecules and uses thereof
03/29/2000EP0988046A1 Oil-free pharmaceutical compositions containing cyclosporin a
03/29/2000EP0988043A1 Method and product using sturgeon notochord for alleviating the symptoms of arthritis
03/29/2000EP0988042A1 A combination therapy for hiv infections
03/29/2000EP0988021A1 Keratin fibre oxidation dyeing composition and dyeing method using same
03/29/2000EP0987943A1 A novel method of detecting and treating cancer
03/29/2000EP0987942A1 Pharmaceutical composition and methods for using it
1 ... 2408 2409 2410 2411 2412 2413 2414 2415 2416 2417 2418 2419 2420 2421 2422 2423 2424 2425 2426 2427 2428 ... 3163